XFOR•benzinga•
X4 Pharmaceuticals shares are trading higher after the company announced an exclusive licensing agreement with Norgine to commercialize Mavorixafor in Europe, Australia, and New Zealand.
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 13, 2025 by benzinga